Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J., ...More

LANCET, vol.389, no.10066, pp.255-265, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 389 Issue: 10066
  • Publication Date: 2017
  • Doi Number: 10.1016/s0140-6736(16)32517-x
  • Title of Journal : LANCET
  • Page Numbers: pp.255-265


Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.